
ACR issues guidance for breast biopsy needle shortage
The guidance offers triage, conservation, inventory, case-prioritization, and patient-communication strategies for practices affected by the stereotactic breast biopsy needle shortage.
Company

The guidance offers triage, conservation, inventory, case-prioritization, and patient-communication strategies for practices affected by the stereotactic breast biopsy needle shortage.

ACR supported less frequent law-enforcement coordination and removal of weekly verification requirements but urged NRC to keep annual refresher training for security personnel.

The American College of Radiology has warned that stereotactic breast biopsy needle shortages are disrupting breast imaging practices. The FDA lists the devices in shortage with availability estimated through Q4 2026.

The ACR Council approved the ACR-SIIM Practice Parameter for Imaging Artificial Intelligence at ACR 2026. The guidance covers AI selection, predeployment testing, monitoring, governance, and privacy.

The Cancer Doesn’t Care Fund will support pilot programs, community partnerships, technology development, and policy research for earlier cancer detection.